Senior Manager, IT Applications, Pulmovant

Pulmovant is a Roivant-backed clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases. Pulmovant ’s first investigational candidate, mosliciguat, is designed to provide a novel, once-daily, inhaled treatment option for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Mosliciguat is a potential first-in-class soluble guanylate cyclase activator with a differentiated mechanism of action currently being evaluated in the Phase 3 PHrontier global clinical trial in PH-ILD, but with potential broad applicability across the PH and ILD disease landscape.

Pulmovant recently announced positive results from its Phase 2 PHocus study evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. PHocus met both primary and secondary endpoints including the highest ever reported pulmonary vascular resistance (PVR) reduction in any randomized controlled PH trial. The robust results, in conjunction with mosliciguat’s once-daily, inhaled administration and potential first-in-class sGC activator profile, strongly position it as a potential single agent treatment and combination therapy for patients with PH-ILD. These data represent a significant advancement in a devastating disease that affects ~200,000 patients with no or very limited treatment options. A Phase 3 trial is currently underway. More details can be found in the press release here.

As part of the Roivant family of companies, Pulmovant leverages the power of collaboration and innovation to drive progress.

For more information, please visit .
About Roivant:

Roivant specializes in developing transformative medicines at an accelerated pace through the launch of nimble biopharmaceutical and health technology entities, each meticulously tailored to address a specific medical need. Since its inception in 2014, Roivant has achieved the following critical milestones in support of its vision: built over 20 Vants; 12 consecutive positive Phase 3 trials; 9 FDA approvals; 5 successful IPOs; >$6B in capital raised; >$10B in global pharma partnerships and proceeds; and continued pipeline expansion across various modalities and therapeutic areas through in-licensing and acquisition of novel product candidates and technology platforms. In addition to a robust clinical stage pipeline, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Position: Senior Manager, IT Applications

Summary: The Senior Manager, IT Applications manages the enterprise application portfolio that runs Pulmovant 's business and regulated operations. This role oversees the day-to-day performance, compliance, and lifecycle of both GxP/clinical systems (e.g., Veeva Vault, DocuBridge…) and core enterprise IT applications (ITSM, SharePoint), while partnering closely with Clinical, Regulatory, Quality, Finance, and HR stakeholders. The ideal candidate is a hands-on systems leader who is equally comfortable managing validated, compliance-critical platforms and general enterprise IT tools, and who brings the collaboration, adaptability, analytical rigor, and efficiency mindset needed in a fast-moving, regulated biotech.

Key   Duties and Responsibilities
System Management & Operations

- Manage and maintain the enterprise application portfolio, including validated GxP/clinical systems (Veeva Vault — QualityDocs, VaultTraining, QMS,RIM, eTMF, CDMS) and general enterprise IT applications (ITSM platform, M365/collaboration tools,).

- Serve as the primary owner for system uptime, performance, configuration, and issue resolution across supported applications.

- Lead system implementations, upgrades, integrations, and decommissions, coordinating computer system validation (CSV) activities with Quality where